Idorsia Ltd (SIX:IDIA) has received FDA approval for 25- and 50-mg doses of Quviviq (daridorexant), a dual orexin receptor antagonist. Quiviviq is the first compound in its pipeline to win FDA approval. The drug works differently from traditional benzodiazepines, which modulate neuronal activity. By contrast, daridorexant inhibits the binding of orexins to reduce excessive wakefulness.…